Riviciclib

Non Chimik:

2-(2-chlorophenyl)-5,7-dihydroxy-8-((2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-chromen-4-one hydrochloride

Kòd SMILES:

O=C1C=C(C2=CC=CC=C2Cl)OC3=C1C(O)=CC(O)=C3[C@H]4[C@H](CO)N(C)CC4.[H] Cl

Kòd InChi:

InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28- 21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12 -,14+;/m1./s1

InChi kle:

OOVTUOCTLAERQD-OJMBIDBESA-N

Mot:

P276-00; P-276-00; P 276-00; P-27600; P 27600; P 27600; Riviciclib, Riviciclib HCl

Solibilite: 

Depo: 

Deskripsyon:

Riviciclib, ke yo rele tou P276-00, se yon inibitè flavon ak siklin kinaz depandan (CDK) ak potansyèl aktivite antineoplastic. P276-00 seleksyone mare ak inibit Cdk4/cyclin D1, Cdk1/cyclin B ak Cdk9/cyclin T1, serine/threonine kinases ki jwe wòl kle nan règleman sik selilè a ak pwopagasyon selilè. Anpèchman kinaz sa yo mennen nan arè sik selil pandan tranzisyon G1 / S, kidonk mennen nan yon endiksyon nan apoptoz, ak anpèchman nan pwopagasyon selil timè.

Sib: CDK